Events and Presentations
Immunic's MS R&D Day in San Francisco
Could Vidofludimus Calcium be the First Neuroprotective Treatment Option for Multiple Sclerosis?
The event focussed on Immunic’s MS development program and its late-stage clinical asset, first-in-class Nurr1 activator vidofludimus calcium. Immunic’s management highlighted latest developments in the MS landscape as well as recent preclinical and clinical data supporting the neuroprotective potential of vidofludimus calcium. In addition, a leading expert on nuclear receptor research and autoimmune diseases, Dr. Zuoming Sun, attended the event and was available for insights and questions from the audience.
